BlissBio Completes Series B++ Financing, Invested by Eisai

      HANGZHOU, June 06, 2023 --- Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announced the completion of Series B++ financing invested by Eisai Co., Ltd (“Eisai”).

      The fund will be used to advance the multi-site clinical studies, pre-clinical studies and regulatory submissions of the products in the pipeline. As announced on May 8, 2023, Eisai and BlissBio entered into a clinical trial collaboration agreement with option for strategic collaboration with Eisai for BB-1701.    

      “Over the last five years,” said Dr. Ziping Wei, Co-founder, Chairman, and CEO of BlissBio, “we have established a differentiated and promising ADC pipeline, and currently 3 products have entered into the clinical stage. More potential pre-clinical candidates are to come. We are excited to have a deeper collaboration with Eisai. With the investment support and clinical collaboration as well, I believe we will bring new treatment options sooner to patients who are in need worldwide.”

About Bliss Biopharmaceutical (Hangzhou) Co., Ltd

      Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated on discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Qiantang Area, Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs.

      For more information please visit https://www.blissbiopharma.com

About Eisai Co., Ltd    

      Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as our human health care (hhc) Concept), the company aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, the company strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

      In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.

      For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter, LinkedIn and Facebook.

Media Inquiries

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

TEL: +86-0571-86808367

E-mail: office@blissbiopharma.com